Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension
The goal of this clinical trial is to learn if an exercise programme started shortly after diagnosis improves the fitness and mental wellbeing of patients with pulmonary hypertenion over and above medication alone.
- Trial name
- NCT07366879
- Testing
- Home-based, remotely delivered, supervised Exercise programme
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- Golden Jubilee National Hospital
Idiopathic Pulmonary Arterial Hypertension
Features of the Clinical Course and Prognosis in Patients With Idiopathic Pulmonary Hypertension When Using Modern Strategies of Specific Therapy
This study will be performed based on a retrospective analysis of the cases of 150-170 patients with IPAH observed at the Research Institute of Clinical Cardiology over the past 10 years, for a comparative assessment of the…
- Trial name
- NCT06587074
- Where
- Russia
- Volunteers
- 150 people
- Sponsor
- Russian Cardiology Research and Production Center
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
The purpose of this study is to determine if patients with pulmonary hypertension and mildly elevated heart pressure known as PCWP will exhibit different patterns on echocardiography and that these patterns will predict treatment…
- Trial name
- LV strain (NCT01800292)
- Testing
- sildenafil
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Pulmonary Arterial Hypertension
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.
- Trial name
- IMPROVE-PAH (NCT07365332)
- Testing
- IKT-001
- Where
- 43 sites in United States, Argentina and 12 more
- Volunteers
- 486 people
- Sponsor
- Inhibikase Therapeutics
Pulmonary Arterial Hypertension
Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography
An echocardiogram using Definity contrast can provide the same information as the standard right heart catheterization.
- Trial name
- NCT02028299
- Testing
- 2D doppler echo with Definity solution
- Volunteers
- 38 people
- Sponsor
- George Washington University
Pulmonary Arterial Hypertension
Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
The purpose of this 8-week study is to compare the effects of switching from intravenous Flolan to intravenous Remodulin therapy. Remodulin (treprostinil sodium) is an approved therapy for pulmonary arterial hypertension (PAH).
- Trial name
- NCT00439946
- Testing
- treprostinil, Crono Five ambulatory pump
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension
The study is a single center randomised, double-blind, placebo-controlled crossover study to assess the effects of beetroot juice in patients with pulmonary arterial hypertension.
- Trial name
- BEET-PAH (NCT02000856)
- Testing
- Beetroot juice
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Uppsala University
Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia (FETO)
The purpose of this research is to gather information on the safety and effectiveness of a new procedure called Fetoscopic Endoluminal Tracheal Occlusion (FETO).
- Conditions
- Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia, Pulmonary Artery Hypertension
- Trial name
- FETO (NCT03138863)
- Testing
- BALT GoldbBAL2 Detachable Balloon, Catheter System
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rodrigo Ruano
Pediatric Pulmonary Hypertension
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosentan, will result in better…
- Trial name
- MoD (NCT04039464)
- Testing
- Mono-Therapy with Sildenafil, Duo-Therapy with Sildenafil + Bosentan
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Johns Hopkins University
Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease)
The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients
ECMO(Extracorporeal membrane oxygenation) is being essential for cardiopulmonary failure patients. There are two types of ECMO, which is veno-veno (V-V) that can be used in respiratory failure patients and veno-arterial (V-A)…
- Conditions
- Interstitial Pulmonary Fibrosis ARDS, COPD (Chronic Obstructive Pulmonary Disease), Bronchiectasis, Lymphangioleiomyomatosis
- Trial name
- NCT02859194
- Testing
- Veno-veno-arterial ECMO
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Yonsei University
Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic
Medication Reconciliation in Pulmonary Hypertension
Pulmonary hypertension (PH) is a life threatening condition. In PH, pulmonary arterial hypertension (PAH) and chronic thrombo-embolic chronic pulmonary hypertension (CTEPH) are two rare diseases requiring specific and complex…
- Conditions
- Pulmonary Hypertension, Pulmonary Hypertension Chronic Thromboembolic, Pulmonary Arterial Hypertension
- Trial name
- OPTICARE-HTP (NCT04744584)
- Testing
- Medication reconciliation
- Where
- France
- Volunteers
- 129 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Arterial Hypertension
Neuromuscular Electrical Stimulation in Pulmonary Arterial Hypertension
This study aimed to investigate the effects of neuromuscular electrical stimulation on peripheral muscles and other physical and psychosocial variables in patients with pulmonary arterial hypertension.
- Trial name
- NCT03612115
- Testing
- Neuromuscular electrical stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 31 people
- Sponsor
- Dokuz Eylul University
Pulmonary Arterial Hypertension
Oral Iron Supplementation in Pulmonary Hypertension
The purpose of this study is to investigate the effects of iron supplementation in patients with pulmonary arterial hypertension and iron deficiency.
- Trial name
- NCT01446848
- Testing
- iron supplement
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The Cleveland Clinic
Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT01365585
- Testing
- sildenafil citrate
- Where
- 2 sites in Germany, Ireland
- Volunteers
- 227 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
An open label study to assess the safety and efficacy of tocilizumab in group 1 pulmonary arterial hypertension patients
- Trial name
- TRANSFORM-UK (NCT02676947)
- Testing
- Tocilizumab
- Where
- United Kingdom
- Volunteers
- 29 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Pulmonary Arterial Hypertension
Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)
Patients with pulmonary arterial hypertension (PAH) are at much higher risk of death if the RV (right ventricle) is weak. The purpose of this study is to get a better understanding of the factors that determine RV adaptation and…
- Trial name
- ISS (NCT02074449)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Arizona
Pulmonary Hypertension
Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
AMB-220-E is an international, multicenter, open-label study examining the long-term safety of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study NCT00046319, "A Phase II, Randomized, Double-Blind…
- Trial name
- NCT00424021
- Testing
- ambrisentan
- Volunteers
- 54 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
Evaluation of the Role of Epstein-Bar Virus in Patients With Pulmonary Arterial Hypertension
Evaluate the role of Epstein-Barr virus infection in PAH (Idiopathic and connective tissue disease). This by obtaining a blood sample from the PAH patients undergoing right heart cathetrization as well as obtaining the…
- Trial name
- NCT06550648
- Testing
- Right Heart Catheterization (Swan Ganz Catheter)
- Where
- Egypt
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Cairo University
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Multimodality RV Phenotyping for Risk Stratification and Short-Term Outcomes in Group 1 PAH
The MIRROR-PAH is a single-center, prospective, observational cohort study evaluating the incremental value of multimodality imaging-derived right ventricular characteristics for risk stratification in patients with Group 1…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Right Ventricular Function
- Trial name
- MIRROR-PAH (NCT07667673)
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics